Early Neurodevelopmental Outcomes Following Exposure to General Anesthesia in Infancy: EGAIN, a Prospective Cohort

Choon Looi Bong1, Duncun Ho2, John Carson Allen3

  • 1Department of Pediatric Anesthesia, KK Women's and Children's Hospital.

Insights

A single exposure to general anesthesia (GA) in infancy did not impact cognitive, language, or motor skills at 24 months. However, GA-exposed children showed subtle behavioral differences and neurophysiological changes, suggesting a need for advanced assessments.

Area of Science:

  • Pediatric Neurodevelopment
  • Anesthesiology
  • Developmental Psychology

Background:

  • Early-life general anesthesia (GA) effects on neurodevelopment are debated in humans, despite animal studies indicating negative neural outcomes.
  • Previous human research on early GA exposure and neurodevelopment has yielded inconsistent findings.
  • This study investigates the impact of a single GA exposure for minor surgery on healthy children's neurodevelopment.

Purpose of the Study:

  • To assess the neurodevelopmental effects of a single general anesthesia exposure in healthy infants.
  • To utilize clinical, behavioral, and neurophysiological measures to evaluate outcomes at multiple time-points.
  • To compare neurodevelopmental trajectories between GA-exposed and non-exposed children.

Main Methods:

  • A prospective cohort of 250 healthy infants undergoing GA for minor surgery before 15 months was compared to a non-exposed cohort.
  • Clinical assessments included Bayley Scales of Infant and Toddler Development-III (BSID-III) and Child Behavior Checklist (CBCL1½-5) at 24 months.
  • Experimental tests for memory and attention, along with event-related potentials (neurophysiology), were conducted at 6 and 18 months.

Main Results:

  • No significant differences were observed in cognitive, language, or motor domains of the BSID-III at 24 months.
  • GA-exposed children exhibited poorer parent-reported scores for general adaptability (BSID-III) and higher internalizing behavior (CBCL1½-5).
  • Differences in 4 experimental tests related to memory and attention, and neurophysiological measures were detected at 6 and 18 months.

Conclusions:

  • Early single exposure to general anesthesia did not impair major neurodevelopmental outcomes by 24 months.
  • Subtle behavioral differences and altered neurophysiological responses were evident in infancy.
  • Neurophysiological assessments are valuable complements to clinical evaluations for understanding early GA exposure impacts.
Abstract

Related Concept Videos

General Anesthesia: Overview01:24

General Anesthesia: Overview

Anesthesia is a medical procedure that uses drugs for CNS suppression to enable painless surgeries and procedures. The selection of anesthetics is influenced by their pharmacokinetic properties, side effects, and patient characteristics. Various types of anesthesia include general, local, regional, spinal, and inhalational.
General anesthesia induces unconsciousness in the whole body, while the others target specific areas or sensations. It is administered to minimize adverse effects, maintain...
309
Stages of General Anesthesia01:22

Stages of General Anesthesia

Various sedation levels offer significant advantages in facilitating procedural interventions for patients undergoing medical or invasive surgical procedures. These levels span from anxiolysis to general anesthesia, providing a spectrum of sedative effects to cater to specific patient needs. Anxiolysis reduces anxiety and is achieved through minimal sedation, enabling patients to remain awake and responsive while feeling more at ease during the procedure. This level can benefit minor...
753
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
212